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ABSTRACT
The increased presence of sialylated glycans on the tumor surface has been linked 
to poor prognosis, yet the effects on tumor-specific T cell immunity are hardly studied. 
We here show that hypersialylation of B16 melanoma substantially influences tumor 
growth by preventing the formation of effector T cells and facilitating the presence of 
high regulatory T cell (Treg) frequencies. Knock-down of the sialic acid transporter 
created “sialic acid low” tumors, that grew slower in-vivo than hypersialylated 
tumors, altered the Treg/Teffector balance, favoring immunological tumor control. 
The enhanced effector T cell response in developing “sialic acid low” tumors was 
preceded by and dependent on an increased influx and activity of Natural Killer (NK) 
cells. Thus, tumor hypersialylation orchestrates immune escape at the level of NK and 
Teff/Treg balance within the tumor microenvironment, herewith dampening tumor-
specific T cell control. Reducing sialylation provides a therapeutic option to render 
tumors permissive to immune attack.
INTRODUCTION
Innate immune cells play a crucial role in the 
immune response against tumors. Particularly, dendritic 
cells (DCs), macrophages and NK cells are involved in the 
first phase of the process known as cancer immunoediting, 
where these cells detect the presence of a developing 
tumor and coordinate as well as co-operate with the 
adaptive immune system to eradicate the tumor [1]. 
Specific activation of naive tumor-specific T lymphocytes 
by DCs is required to generate an army of effector CD8+ 
and CD4+ T cells that can effectively eliminate tumor cells. 
Activated CD8+ T cells acquire effector functions such as 
cytolytic activity and/or production of interferon (IFN)-γ 
and tumor necrosis factor (TNF)[2]. Tumor-specific CD4+ 
effector T cells contribute to tumor eradication either 
via direct tumor cell killing [3] or via the activation of 
macrophages at tumor sites [4]. Moreover, activated CD4+ 
T cells aid induction of memory CD8+ T cells, which can 
maintain long-term tumor control.
Next to cytotoxic T cells, also NK cells have the 
capacity to lyse tumor cells. Yet, in contrast to T cells, NK 
cells represent the first line of defense against transformed 
cells. Low or absent expression of MHC-I triggers NK 
cell effector functions, which include release of IFN-γ 
and cytotoxic granules and induction of apoptosis of 
target cells. High frequencies of intra-tumoral NK cells 
have been associated with good prognosis of patients 
[5]. Hence, alterations in frequency and function of 
innate and T cells aid tumor immune escape. Indeed, 
DCs and macrophages in the tumor microenvironment 
are characterized by an anti-inflammatory or tolerogenic 
phenotype promoting the induction of anergic and/or 
regulatory T cells (Treg) [6]. Furthermore, high numbers 
of both natural as well as induced regulatory T cells 
(nTregs and iTregs) infiltrate into the tumor site [7, 8] and 
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together with tolerogenic DCs and macrophages they act 
in concert to hamper the influx and function of effector T 
cells [7–9].
Tumor cells have been shown to display aberrant 
glycosylation [10, 11]. In particular, increased levels of 
sialic acids, driven by enhanced expression and activity 
of beta-galactoside α2,6-sialyltransferase 1 (ST6Gal-1) 
and/or α-N-acetylgalactosaminide α2,6-sialyltransferase 1 
(ST6GalNAc-I), have been detected, which often correlate 
with tumor invasion and poor prognosis of malignancies 
[12–14]. Sialic acids are the outermost monosaccharides 
on glycan chains of glycoproteins and glycolipids, 
attached to the underlying glycans with α2,3-, α2,6- or 
α2,8-linkage [13] and as such the recognition elements for 
selectins and sialic acid-binding Ig-like lectins (siglecs)
[13, 15]. The negative charge of highly abundant sialic 
acids causes dissociation from the primary tumor and 
spreading of tumor cells. Binding to selectins expressed 
on endothelial cells allows tumor cells to disseminate 
[16–18], whereas binding to siglecs allows interaction 
with the immune system. 
We here investigated whether the increased presence 
of sialylated glycans on the surface of tumors promotes 
cellular immune evasion by interfering with the T effector/
Treg balance regulated by innate immune cells.
RESULTS
Reduction of sialic acids on B16 surface antigens 
empowers anti-tumor immunity
To investigate the influence of tumor-expressed 
sialic acids on anti-tumor immunity we reduced their 
presence on the hyper-sialylated cell surface of murine 
B16 melanoma by knockdown of the Slc35a1 gene 
encoding the Golgi-based CMP-sialic acid transporter [19]. 
Using this strategy, B16 cells with sustained reduction 
of surface sialylation were created, which in contrast to 
other methods such as sialidase treatment, permits long-
term immune monitoring in the tumor. Importantly, the 
sialic acid content of the B16 remains unaffected, only 
the addition of the sialic acid residues to growing glycan 
chains on glycoproteins and glycolipids is impeded. 
Slc35a1 knockdown was confirmed using qRT-PCR and 
specifically decreased the quantity of α2,6-linked sialic 
acids on the B16 surface compared to B16 cells treated 
with a non-targeting shRNA (hereafter called B16SLC35A1 
and B16scrambled, respectively) as shown using the plant 
lectins Sambucus Nigra and Maackia Amurensis (SNA and 
MAA-II, Figure 1A, 1B). B16scrambled tumors were already 
visible on day seven after injection into immunocompetent 
C57BL/6 mice and grew substantially faster and larger 
than sialic acid low B16SLC35A1 tumors, which became 
detectable around day 15 and remained much smaller in 
size for a prolonged period (Figure 1C). Since aberrant 
sialylation has been correlated with the invasive properties 
of tumors, we evaluated whether the reduction of α2,6-
sialic acids on B16 altered these characteristics in-vitro. 
However, no difference between B16SLC35A1 and B16scrambled 
tumor cells in binding to plates coated with tumor-derived 
extra-cellular matrix components could be observed 
(Figure 1D). Additionally, the proliferative capacity was 
not affected as indicated by cell-cycle analysis (Figure 1E). 
Using the scratch assay we ascertained that the B16SLC35A1 
and B16scrambled tumors migrated at the same rate and closed 
the gap within 28 hours (Figure 1F). B16scrambled tumors 
showed comparable characteristics to unmodified WT B16 
tumor cells (Supplementary Figure 1A–1D). 
As a reduction of α2,6-sialic acids on B16 surfaces 
did not alter tumor intrinsic characteristics in-vitro, we 
hypothesized that the reduced growth of B16SLC35A1tumors 
in-vivo arose from changes in the host’s anti-tumor 
immune response. At time of sacrifice, significant higher 
CD4+ T cell numbers were detected within the tumor-
infiltrating lymphocytes (TILs) and tumor-draining 
lymph nodes (TDLN) of B16SLC35A1 tumors (Figure 1G). 
Notably, in the B16SLC35A1 microenvironment the fraction 
of Foxp3+ within the CD4+ T cell population was strongly 
reduced. Together with the elevated IFN-γ levels 
secreted by B16SLC35A1-infiltrating lymphocytes upon 
ex-vivo re-stimulation (Figure 1H), these findings suggest 
that the CD4+ and CD8+ T cells in B16SLC35A1 tumors 
are effector rather than tolerogenic T cells. Despite 
the strong reduction in Foxp3+ T cells within the CD4+ 
T cell population at this stage of tumor growth, the CTL/
Treg ratio in the B16SLC35A1 tumor was not different from 
that in B16scrambled tumors (Figure 1G). In contrast to our 
observation on TILs, no reduction in Foxp3+CD4+ T cells 
was found in TDLNs of B16SLC35A1 tumors (Figure 1G). 
Furthermore, no significant differences in T cell numbers 
and phenotype were observed in the spleens of tumor-
bearing mice, indicating that anti-tumor immunity is 
confined to the tumor-microenvironment (Supplementary 
Figure 1E). Furthermore the comparable low MHC-I and 
MHC-II expression levels on the two tumor cell lines rules 
out improved recognition of B16SLC35A1 by tumor-reactive 
CD8+ and CD4+ T cells (Figure 1I).
Together, these findings clearly show that a 
reduction of sialic acids on tumor surfaces evokes a 
switch in the type of immunity in the tumor area: instead 
of immunosuppressive Treg IFN-γ-producing TILs cells 
are present that may control tumor growth.
Sialic acids on tumors dampen activity of NK 
cells
To analyze whether the delayed growth of B16SLC35A1 
tumors in-vivo was paralleled by variations in innate cell 
subsets, which are predominantly involved in the first 
phases of cancer immunoediting, mice were sacrificed 
18 days after tumor implantation, coinciding with early 
phases of B16SLC35A1 tumor development (Figure 2A). 
Oncotarget8773www.impactjournals.com/oncotarget
Figure 1: Reduced sialic acid levels on B16 melanoma decline Treg frequencies and increase effector T cell numbers 
and tumor control. (A) slc35A1 gene expression was analyzed in B16SLC35A1 and B16scrambled cells by qRT-PCR and normalized to GAPDH; 
the mean ± s.e.m of duplicate measurements is shown (n = 4 independent analyses; ***P < 0.001). (B) Detection of a2-6- and a2-3-linked 
sialic acids using the plant lectins SNA and MAA-II on B16SLC35A1 (black line) and B16scrambled (dashed line) tumors by flow cytometry. Grey 
filled histograms represent conjugate control. n = 3 independent experiments. (C) Tumor growth in B16SLC35A1 and B16scrambled tumor-bearing 
mice (n = 7/group), indicated as mm2 (mean ± s.e.m). Shown is one of two independent experiments. (D) Tumor cell adhesion to matrigel-
coated plates. Results shown as percentage of adhering cells (mean ± s.e.m) and represent 3 independent experiments. ns., not significant. 
(E) Cell cycle analysis of B16SLC35A1 and B16scrambled tumors by DNA content. Percentage of cells in G0/G1 interphase and G2/M mitotic 
phase are indicated. Results represent 3 experiments. (F) Scratch assay to assess migratory capacity of B16SLC35A1 and B16scrambled tumors. 
Left, Bright-field images (200 ×) of confluent tumor cells showing re-growth following in-vitro scratch. Right, quantification of distance 
between edges of linear scratch. Data represent 3 independent experiments. ns, not significant. (G) Percentage of total CD4+, CD8+ 
and Foxp3+CD4+ T-cells as well as CTL/Treg ratio in tumor and TDLN from tumor-bearing mice as detected by flow cytometry at time 
of sacrifice. Dots represent individual mice (n = 11) of 2 independent experiments. Bars indicate median/group, n.s. = not significant; 
*P < 0.05; **P < 0.01. (H) IFN-γ levels secreted by TILs from B16SLC35A1 and B16scrambled tumors. Data represent 2 independent experiments, 
*P < 0.05. (I) MHC-I and MHC-II expression on B16SLC35A1 and B16scrambled tumors before injection into mice. Plots represent two independent 
measurements.
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Analysis of the T cells within B16SLC35A1 tumors revealed 
the same increase in total CD4+ T cells found at a later 
stage (i.e. 40 days after implantation; Figures 2B and 1G) 
as well as a markedly lower Foxp3+ fraction within the 
CD4+ T cell compartment than in B16scrambled tumors 
(Figure 2B). No significant changes in tumor-infiltrating 
CD8+ T cells were detected at this early stage of 
tumor development (Figure 2B). Similar as before the 
reduced frequency of CD4+ Tregs in B16SLC35A1 tumors 
was concomitant with increased IFN-γ production 
by infiltrating lymphocytes, indicating a shift from T 
cell tolerance towards T cell immunity that sets stage 
early after tumor implantation (Figure 2C). This is also 
underlined by the significant higher CTL/Treg ratio in the 
B16SLC35A1 tumors compared to that in B16scrambled tumors 
at this early stage of B16SLC35A1 tumor growth (Figure 2B).
Interestingly, B16SLC35A1 tumors contained 25% of 
NK1.1+CD3− NK cells, while in B16scrambled tumors only 
10% was detected (Figure 3A). NK cells are amongst the 
first responders during tumor development, where they 
actively kill the transformed cells by secreting IFN-γ 
and/or release of cytotoxic granules. This function may 
be inhibited in hypersialylated tumors as indicated by 
recent in-vitro studies [24, 25]. Indeed, the IFN-γ levels 
in the supernatants of in-vitro NK and tumor cell co-
cultures clearly demonstrate that a reduction in sialic 
acids increased the IFN-γ production by NK cells, at 
each E:T ratio tested (Figure 3B). In addition to its 
cytolytic effects, IFN-γ can also induce tumor cells to 
produce chemokines that attract immune effector cells, 
such as CXCL10 (IP-10) [20, 21]. The presence of 
IFN-γ increased the levels of IP-10 mRNA in B16SLC35A1 
but not in B16scrambled (Figure 3C). Of note, both tumor 
types expressed equal levels of IFN-γ receptor mRNA 
(Supplementary Figure 1F). Furthermore, we found 
that in contrast to B16scrambled, B16SLC35A1 did not increase 
IL-10 and TGF-β mRNA levels in the presence of IFN-γ, 
thus making the tumor micro-milieu of the sialic acid low 
tumor less tolerogenic (Figure 3C). IFN-γ also resulted 
in an significantly increased expression of MHC-I on 
B16 cells, however, no differences between B16scrambled 
and B16SLC35A1 were observed (Figure 3D). Similar 
observations were made for MHC-II expression levels, 
although these were only moderately increased by IFN-γ.
Thus, hyper-sialylated tumor cells paralyze the 
inflammatory program of NK cells and herewith maintain 
a tolerogenic environment. 
Presence of NK cells is required to evoke the 
switch in T cell response in sialic acidlow tumors
The presence of higher numbers of IFN-γ-secreting 
NK cells in B16SLC35A1 tumors (Figure 3A) as well as 
the immunogenic effect of IFN-γ on the tumor milieu, 
suggests that NK cells play a relevant role in the control 
of B16SLC35A1 growth. To test this, mice challenged with 
B16SLC35A1 tumors were depleted of NK cells by treatment 
with anti-NK1.1 antibodies (Supplementary Figure 1G). 
As observed previously, B16SLC35A1 tumors grew slower and 
were smaller in size when implanted in WT NK-competent 
mice, leading to survival of mice 35 days after tumor 
transplantation (Figure 4A). However, NK depletion drove 
B16SLC35A1 tumors to grow at a similar rate as B16scrambled 
tumors (Figure 4A). Of note, growth of B16scrambled tumors 
was only slightly enhanced when NK cells were depleted 
(Supplementary Figure 1G). Furthermore, the increased 
infiltration of CD4+ and CD8+ T cells into B16SLC35A1 tumors 
was absent when NK cells were depleted (Figure 4B). 
This was mirrored by the absence of effector T cells in 
these mice: IFN-γ-producing CD4+ and CD8+ T cells were 
only detected in B16SLC35A1 tumors (Figure 4C). Although 
depletion of NK cells did not alter the proportion of 
Foxp3+CD4+ T cells within B16SLC35A1 tumors, the CTL/
Treg ratio was only in favor of tumor control in NK replete 
B16SLC35A1. In contrast to the tumor environment, Treg 
numbers were significantly higher in the TDLN of NK cell 
depleted B16SLC35A1 tumor bearing mice (Figure 4B).
In summary, these data unveil a clear and versatile 
role for the levels of sialic acids on tumors regulating NK 
cell mediated initiation of potent anti-tumor immunity.
DISCUSSION
Here we show that reducing sialic acids on the 
surface of melanoma cells evokes the generation of large 
numbers of effector T cells that infiltrate the tumor area 
and simultaneously dampens the intra-tumoral presence 
of Foxp3+ Tregs, together curtailing tumor growth. 
Furthermore, we provide evidence that this switch in T cell 
response from tolerogenic to immunogenic in sialic acidlow 
melanomas is ignited by NK activation as their depletion 
abolishes effector T cell induction. 
In this study we reduced the amounts of sialic acids 
on the murine B16 melanoma surface to assess the impact 
of alterations in sialic acids on the anti-tumor immune 
response. Slc35A1 knock down significantly reduced the 
presence of α2,6-linked sialic acids on the B16 surface. 
Besides melanoma, also other invasive and metastatic 
tumors (e.g. colon and breast carcinoma) present an 
aberrant expression of α2,6-sialic acids mainly because 
of the overexpression of ST6Gal1 sialyltransferase, which 
adds terminal sialic acid moieties on N-linked glycans 
[14]. It has been shown that enhanced expression of α2,6-
sialic acid on tumors promotes cell detachment from the 
tumor mass as well as their invasiveness by facilitating 
interactions with matrix proteins [22, 23]. 
We observed that in-vivo B16SLC35A1 tumors grew 
significantly slower and remained much smaller in size 
than B16scrambled tumors for a long period, resulting in better 
survival of mice bearing B16SLC35A1 tumors. Since in-vitro 
intrinsic properties of B16-OVA such as migratory and 
adhesion abilities were not affected by the reduction of 
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Figure 2: SLC35A1 knockdown in tumors alters intra-tumoral CD4+ Tregs frequencies at early stages of tumor 
development. Mice (n = 6/group) were inoculated with either B16SLC35A1 and B16scrambled tumors and (A) tumor growth represented in mm2 
(mean ± s.e.m) was measured every 2–3 days until day 18. (B) Mice were sacrificed 18 days after tumor injection and percentages of total 
CD4+ T cells, CD8+ T cells, and of Foxp3+CD4+ T cells in the tumor and TDLNs from tumor-bearing mice as detected by flow cytometry. 
CTL/Treg ratios were calculated for each mouse. Dots represent individual mice (n = 6 mice/group; n.s. = not significant; *P < 0.05). Bars 
indicate median of each group. Statistical significance is indicated (Student’s t test). (C) Levels of IFN-γ secreted by TILs from B16SLC35A1 
and B16scrambled tumors upon PMA/ionomycin activation (mean ± s.e.m.; **P < 0.01). Data are representative of 2 independent experiments. 
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α2,6-sialic acids, the delayed growth of B16SLC35A1 tumors 
in-vivo is suggested to be the outcome of improved 
immune control. This is also underlined by our findings 
that CD4+  T cell numbers were increased in the tumor 
and TDLNs as well as the ability of both CD4+ and CD8+ 
T cells to produce IFN-γ. At the same time, frequencies of 
tumor-associated Tregs were strongly diminished in the 
B16SLC35A1 tumors. Thus, reducing sialic acids on the tumor 
surface switches the function of tumor-specific T cells 
from tolerogenic to effector. Notably, both in the early 
as well as the later stages of tumor growth, the effects 
of sialic acidlow tumors on T cell frequency and function 
were mainly evident in the tumor and not in the TDLN, 
which points to strong intra-tumor immune regulation that 
is sufficient to control tumor growth.
This study is the first to show the immunological 
consequences of tumor cell hyper-sialylation. We 
demonstrated that the presence of NK cells, Tregs, 
Figure 3: Increased numbers of intra-tumoral NK cells ignite an immunogenic milieu in B16SLC35A1 tumors via 
IFN-γ. (A) Percentage of NK cells, distinguished as NK1.1+CD3- cells, within B16SLC35A1 and B16scrambled tumors (n = 6 mice/group) 
using flow cytometry. Bars indicate the median of each group; **P < 0.05. (B) NK cells, enriched from naive splenocytes, were incubated 
at indicated E:T ratio’s from B16SLC35A1 and B16scrambled tumors and with IFN-γ was determined by ELISA from the supernatant 4 h later. 
Data are representative of 3 experiments; *P < 0.05. (C) IP-10, IL-10 and TGF-β mRNA levels expressed by B16SLC35A1 and B16scrambled 
tumors in the presence or absence of rm-IFN-γ (n = 4 independent experiments; ***P < 0.001). (D) Flow cytometric analysis of MHC-I 
and MHC-II expression on B16SLC35A1 and B16scrambled cell surface 24 h after culture in the presence of 250 pg/ml rm-IFN-γ. Plots represent 
two independent measurements.
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Figure 4: Depletion of NK cells in sialic acidlow tumor bearing mice abolishes induction of anti-tumor immunity. (A) 
NK-depleted mice were challenged with B16SLC35A1 tumor cells; WT mice were challenged with B16SLC35A1 or B16scrambled tumor cells. Tumor 
growth was assessed at different days after tumor inoculation, indicated as mean mm2 ± s.e.m; n = 7–9 mice/group. Data represent results 
from two independent experiments. (B) TILs and TDLNs were analyzed by flow cytometry to determine the frequency of CD4+ and 
CD8+ T cells and of Foxp3+ of CD4+ T cells. CTL/Treg ratio was calculated for each mouse. Dots represent individual mice. Bars indicate 
median of each group (n = 7–9 mice/group). (C) IFN-γ production by activated CD8+ and CD4+ T cells in TDLN was determined by 
intracellular staining after PMA/ionomycin restimulation ex vivo. Dots represent individual mice; n = 5 mice/group. *P < 0.05, **P < 0.01, 
***P < 0.001. Graphs shown are representative of two independent experiments.
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effector T cells, and probably DCs, is affected and that 
these immune cells cooperate in their mode of action, 
herewith linking hypersialylation with tumor induced 
immune tolerance. The sialic acid binding receptors or 
siglecs are predominantly found on innate immune cells, 
such as antigen presenting cells (APCs) and NK cells [15]. 
On APCs cells, siglecs function as endocytic receptors and 
regulate their activation and cytokine secretion. The CD33/
Siglec-3-related siglec (hCD33rSiglecs) subgroup of 
siglecs possess immunoreceptor tyrosine-based inhibitory 
motifs (ITIMs) in their intracellular portion, which can 
counteract the activating signals triggered by receptors 
containing immunoreceptor tyrosine-based activatory 
motifs (ITAMs) [15]. This suggests that engagement of 
hCD33rSiglecs on innate cells by sialylated antigens 
may result in suppressive effects on the innate immune 
response. Since on the engineered B16SLC35A1 tumors 
mostly α2,6-linked sialic acids were reduced, together 
with our observation that the immune response is affected 
at multiple cellular levels underscores the possibility that 
different siglec receptors expressed on NK, Tregs and DCs 
may mediate sialic acid-tumor immune evasion.
Analysis of the immune composition in the early 
stage of tumor growth revealed increased frequencies of 
NK cells in B16SLC35A1 tumors compared to B16scrambled 
tumors. Moreover, NK cells engaging B16SLC35A1 tumor 
cells secreted elevated amounts of IFN-γ compared to 
those engaging B16scrambled cells. A similar enhanced IFN-
γ-secretion by NK cells was reported in a study in which 
sialylation of the chemically induced fibrosarcomas was 
reduced via sialidase treatment or when the sialylation 
status of tumor cell surfaces was remodeled using synthetic 
glycopolymers [24, 25]. Murine NK cells express siglec 
receptors such as Siglec-E and Siglec-G [26, 27], which 
bear specificity for α2-6-linked sialylated branches [28]. 
Thus, it is possible that the reduction of α2,6-sialic acids 
on B16 tumor cells diminished siglec-mediated inhibition 
of NK cell functions. Indeed, recent studies showed that 
in-vitro the susceptibility of hypersialyated tumor cells 
to NK cytotoxicity could be blocked by siglec-blocking 
antibodies or de-sialylation of the tumors [24, 29]. The 
absence of this inhibitory interaction paves the way for 
the NK activating receptor NKG2D with its ligands on 
tumors, enhancing IFN-γ secretion and killing capacity of 
NK cells [25]. The augmented numbers of NK1.1+ NK 
cells present in sialic acidlow tumors during the early stages 
of tumor development could be a result of initial activated 
NK cells producing IFN-γ since IFN-γ has been shown 
to mediate recruitment of NK cells to sites of infection 
[30]. This NK cell influx is likely further enhanced by the 
chemokine IP-10, which was highly induced by IFN-γ in 
sialic acidlow tumors. Furthermore, the increased numbers 
of NK cells could also be due to  reduced frequency of 
Tregs in the tumor area, as it has been shown that Tregs 
limit expansion of NK cells by restraining IL-2 from 
effector T cells [31].
The absence of CD4+ and CD8+ effector T cells 
in the B16SLC35A1 tumor microenvironment when NK 
cells were depleted elucidates that the IFN-γ released 
by activated NK cells likely also functions to activate 
DCs [32], which obviously are instrumental in the 
subsequent induction of large amounts of effector T cells. 
Additionally, the released IFN-γ makes the tumor micro-
milieu susceptible for immune attack as we showed that 
IFN-γ reduced production of anti-inflammatory cytokines 
by tumor cells. Next to the IFN-γ released by activated NK 
cells, DC activation may also be the result of diminished 
siglec triggering on DCs. Similar to NK cells, DCs 
also express siglecs, and predominantly Siglec-E. We 
recently showed that Siglec-E-mediated internalization 
of sialylated antigens by DCs provides them with a 
tolerogenic phenotype: these DCs promote the induction 
of Treg. Additionally, the production of pro-inflammatory 
cytokines and ability to induce effector T cell generation 
is significantly reduced in these DCs (Perdicchio et al., 
manuscript under submission). Furthermore, by secreting 
high levels of sialylated gangliosides tumor cells inhibit 
the expression of costimulatory molecules on DCs and 
herewith reduce T cell proliferation [33]. Also, binding of 
sialylated pathogens to siglecs on DCs has been described 
to dampen secretion of pro-inflammatory cytokines [34]. 
DC binding of sialic acid structures on C. jejuni modulates 
the signals DCs provide to naive T cells and that mediate 
T cell activation and polarization. Thus, it is likely that 
enhanced tumor sialylation adds to the generation of 
tolerogenic tumor-associated DCs, which in the tumor 
microenvironment convert naive T cells into Tregs. This 
is also suggested by the finding that sialic acidlow tumors 
were inhabited by lower amounts of Tregs than hyper-
sialylated tumors. Unexpectedly, in sialic acidlow tumors 
that are depleted of NK cells the frequency of Foxp3+ 
Tregs did not return to the levels observed in sialic acidhigh 
tumors. We hypothesized that Tregs expressing NK1.1 
could potentially be co-depleted by the anti-NK1.1 Ab 
treatment. However, this appeared not to be the case as 
we found that the Foxp3+ T cells present in the tumors 
and TDLN lack expression of NK1.1 (Supplementary 
Figure 1I). Moreover, Treg frequencies were increased in 
the TDLN of NK cell depleted mice bearing sialic acidlow 
tumors  (Figure 4B). A decreased amount of Tregs in sialic 
acidlow tumors may alternatively result from impaired 
local expansion of natural Tregs or impaired recruitment 
due to reduced expression of Treg-attracting chemokines 
[8, 35]. Which of these scenarios is involved in creating 
the tolerogenic tumor milieu is subject of current research. 
Our data strongly indicate that reducing sialylation 
may provide a therapeutic option to render tumors 
permissive to immune attack. This could for example 
be accomplished by targeted delivery of an sialic acid-
blocking glyco-mimetic, which was recently shown to 
delay metastasis of B16 melanoma when used as adjuvant 
therapy [36]. Additionally, the use of synthetic small 
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molecules to inhibit sialyltransferase or sialyltransporter 
activity would also allow to tackle tumors that express α2,3- 
or α2,8-linked sialic acids or sialyl-LeX [13]. However, 
whether α2,3- or α2,8-linked sialic acids or sialyl-LeX on 
tumors have similar effects on the immune composition in 
the tumor environment remains to be examined. 
In conclusion, we showed a correlation between 
melanoma hyper-sialylation and the induction of a 
tolerogenic tumor microenvironment marked by high 
amounts of Tregs and tolerized NK cells. Moreover, our 
studies unveiled a crucial role for activated NK cells 
igniting different pathways that result in the generation 
of tumor-specific effector T-cells. Hence, the reduction 
of sialic acids on tumors or blocking siglecs on NK 
cells and/or DCs might have therapeutic implications in 
immunotherapy of tumors. 
MATERIALS AND METHODS
Cells and lentiviral transduction
B16-OVA (murine melanoma; kindly provided by 
Dr. T. Schumacher, National Cancer Institute, Amsterdam, 
The Netherlands) were cultured in DMEM supplemented 
with 10% FCS, 50 U/ml penicillin and 50 µg/ml 
streptomycin (BioWhittaker, Walkersville, MD). 
Sialic acid low B16-OVA (hereafter named 
B16SLC35A1) were generated by transducing B16 with the 
pLKO.1 lentiviral vector containing SLC35A1shRNA. As 
a control, B16-OVA cells were transduced with pLKO.1 
containing non-target shRNA (designated B16scrambled). 
Lentiviral vectors were produced as described earlier 
[37]. In short, HEK293T cells were co-transfected with 
pLKO.1-shRNA and the packaging plasmids (pVSV-G, 
pMDL and pRev-RRE) in the presence of calcium 
phosphate. One day later, medium was replaced by 
serum-free medium and culture supernatant was harvested 
another day later. B16-OVA  were seeded at 105 cells/well 
and transduced with a fixed amount of lentiviral vector 
when 80% confluent. The day following infection, target 
cells were selected with 1 μg/ml puromycin. 
Tumor experiments
For in vivo studies, 1 × 105 tumor cells were 
inoculated subcutaneously into the flank of C57BL/6 
mice (8-12 weeks old; Charles River Laboratories) . 
Mice were sacrificed when tumors reached a diameter of 
1.5 cm and tumors, spleens and lymph nodes were 
removed for analysis by flow cytometry. To deplete 
NK cells, mice were injected i.p. with anti-NK1.1 
antibodies (PK136; mouse IgG2a; 0.2 mg) on days -3, 0, 
4, 8 from the start of tumor challenge. From day 8 on, 
anti-NK1.1 antibodies were injected once a week. All 
experiments were approved by the Animal Experiments 
Committee of the VUmc, Amsterdam.
Tumor-infiltrating lymphocytes, spleens and 
tumor-draining lymph nodes
For isolation of tumor-infiltrating lymphocytes, 
tumors were removed from C57BL/6 mice, cut into 
grain size pieces and incubated in HE medium (RPMI 
medium with 10% FCS, 10 mM EDTA, 20 mM HEPES, 
50 U/ml penicillin, 50 µg/ml streptomycin) supplemented 
with 1 WU/ml Liberase-TL (Roche Diagnostics GmbH, 
Manheim, Germany) and 50 μg/ml DNase I (Roche) for 
30 min at 37°C. Erythrocytes were lysed with ACK lysis 
buffer and tumor-infiltrating lymphocytes were purified by 
ficoll gradient with Lymphoprep (Axis-Shield, UK). 
Tumor-draining lymph nodes and spleens were 
passed through a 100 µm cell strainer (BD Falcon, NJ, 
USA) in Iscove’s Modified Dulbecco’s Medium (IMDM; 
Gibco, CA, USA) to generate single cell suspensions. 
Erythrocytes were lysed with ACK lysis buffer. 
Subsequently, the presence of different immune cells was 
analyzed upon staining with specific antibodies and flow 
cytometry. Alternatively, cells were re-stimulated with 
30 μg/ml phorbol 12-myristate 13-acetate (PMA) and 
500 ng/ml ionomycin (Sigma-Aldrich) for detection of IFN-γ 
in cell supernatants by ELISA  (eBiosciences, CA, USA).
Co-cultures of tumor cells and NK cells
To examine effects of sialylated tumorantigens on 
NK cell function, either total splenocytes or NK-enriched 
splenocytes derived from naive C57BL/6 mice were 
co-cultured at indicated E:T ratio with B16SLC35A1 or 
B16scrambled tumor cells. Four hours after co-culture, the 
amount of IFN-γ in the supernatant was analysed by 
ELISA. To enrich for NK cells, splenocytes from naive 
mice were incubated with  (rat-anti-mouse) antibodies 
directed against MHC-II, CD3, CD4, CD8, F4/80, MAC-1, 
followed by incubation with sheep-anti-rat antibody 
coated magnetic beads. 
To determine effects of NK-derived IFN-γ on 
tumor-expressed chemokines and cytokines, B16SLC35A1 
and B16scrambled were cultured in the presence or absence of 
250 pg/ml IFN-γ for 6 hours and expression of chemokines 
and cytokines was measured by qRT-PCR.
Analysis of cell cycle, adhesion and motility
For cell cycle analysis by DNA content, tumor cells 
were collected and fixed in 70% ethanol o/n at 4°C. After 
washing, tumor cells were resuspended in PBS containing 
10 μg/ml Propidium Iodide and 200 μg/ml RNase A and 
analyzed by flow cytometry. 
For cell adhesion analysis, Nunc-immunoMaxisorp 
plates (Sigma-Aldrich) were coated o/n with 50 ulmatrigel 
(BD Biosciences) 1:25 in PBS buffer. After washing with 
TSM buffer (20 mMTris-HCl, pH 8, 150 mMNaCl, 1 mM 
CaCl
2
, 2 mM MgCl
2
), non-specific binding was blocked 
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with TSM/0,5% BSA . CFSE-labeled tumor cells were 
allowed to adhere for 30 min at 37°C, and non-adherent 
cells were removed by gently washing plates three times 
with pre-warmed TSM/0.5% BSA. Subsequently, bound 
tumor cells were lysed using a 50 mMTris/0,1% SDS 
buffer and fluorescence was detected using a CytoFluor 
(Applied Biosystems, CA, USA). A motility or scratch 
assay was performed as previously described [38]. 
Flow cytometry
The following monoclonal antibodies (derived either 
from BD biosciences or eBioscience) were used:  FITC-
labeled   anti-CD3 (145-2C11), -CD4 (RM4-5), -NK1.1 
(PK136 ebio), -MHC-I (H-2Kb; AF688.5BD),-CD8b 
(eBIOH35); PE-labeled anti-CD8b (eBioH35-17.2), 
-MHC-II (M5/114.15.2) and –NK1.1 (PK136); and APC-
labeled anti-FoxP3 (FJK-169). Biotin-labeled plant-
derived lectin SambucusNigra (SNA) was obtained from 
Vector Labs, CA, USA, and binding was detected with 
PE-labeled Streptavidin (Jackson Immunoresearch, UK). 
qRT-PCR
Total RNA was extracted using the RNeasy kit 
(Qiagen, Valencia, CA) combined with a DNase treatment 
to remove contaminating DNA (Qiagen). cDNA was 
synthesized using the Reverse Transcription System 
kit (Promega, WI, USA) following manufacturer’s 
guidelines. Real time PCR reactions were performed 
using the SYBR Green method in an ABI 7900HT 
sequence detection system (Applied Biosystems), with 
GAPDH as internal control. Samples were analyzed 
in triplicate and normalized to GAPDH. Primers were 
obtained from Invitrogen (Carlsbad, California) and 
sequences were as follows: GAPDH-FWD:GACAACT
CATCAAGATTGTCAGCA;GAPDH-REV:TTCATGAG 
CCCTTCCACAATG;IL-10-FWD:GGACAACATACTG 
CTAACCG;IL-10-REV:GGGGCATCACTTCTACCAG; 
TGFβ-1-FWD:GCTGAACCAAGGAGACGGAATA; 
TGFβ-1-REV:GGGCTGATCCCGTTGATTT;IP-10-
FWD:GACGGTCCGCTGAACTG;IP-10-REV:GCTTCC 
CTATATGGCCTCATT;IFNg-R-FWD:GCTTTGACGAG 
CACTGAGGA;IFNg-R-REV:CCAGCATACGACAGGG 
TTCA;SLC35A1-FWD:CATGGCCTTCCTGGCTCTC; 
SLC35A1-REV:GGTCACCTGGTACACTGCTGC.
Statistical analysis
Prism software (GraphPad 5.0) was used for 
statistical analysis. Student’s t test was to determine 
statistical significance. Statistical significance for all the 
tests, assessed by calculating the P values, was defined as 
P < 0.05.
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